HAT Inhibitor Selective p300/CBP Binding
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for diseases related to p300/CBP, such as cancer and inflammation, lack effective inhibitors that can selectively target and inhibit the activity of p300/CBP, leading to incomplete therapeutic outcomes.
Innovation Solution
Development of a compound represented by formula I, which acts as a histone acetyltransferase (HAT) inhibitor, specifically designed to compete with acetyl-CoA for binding to the catalytic active site of p300/CBP, thereby inhibiting its activity in cancer cells.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If current treatments are used for p300/CBP-related diseases, then general therapeutic effects are achieved, but selective inhibition of p300/CBP activity is insufficient
Solution Approach 1:
The compound is designed to interact specifically with the catalytic active site of p300/CBP through localized molecular features (amino group, carbonyl group, and hydrophobic groups positioned at specific spatial coordinates), enabling selective inhibition of p300/CBP activity while maintaining therapeutic effectiveness for p300/CBP-related diseases
Solution Approach 2:
The compound modifies key parameters of p300/CBP function by competing with acetyl-CoA for binding to the catalytic active site, thereby changing the acetylation state of histones and transcription factors, which leads to selective inhibition of p300/CBP-dependent transcriptional activation in cancer cells
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The compound effectively inhibits p300/CBP activity in cancer cells, showing promise in treating various cancers and inflammatory conditions by selectively targeting and reducing the proliferation of tumor cells.
Implementation Method 1
acts as a histone acetyltransferase (HAT) inhibitor, specifically designed to compete with acetyl-CoA for binding to the catalytic active site of p300/CBP
Data Source
AI summary
Disclosed is a histone acetyltransferase (HAT) inhibitor. Provided are a compound represented by the general formula I, a pharmaceutically acceptable salt, a stereoisomer, an enantiomer, a diastereoisomer, an atropisomer, a racemate, a polymorph, a solvate or an isotope-labeled compound (including deuterium substitution) thereof, a preparation method therefor, a pharmaceutical composition comprising same and use thereof in the treatment of various HAT-related diseases or conditions.